Haleos LabsNSE:HALEOSLABS -0.50%72 EBITDA Margin % is 8.22% as of Mar. 2026, which is 31% below its 10-year median of 11.94. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,123.78 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 935 Biotechnology companies, Haleos Labs ranks better than 77.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Haleos Labs's EBITDA for the
three
months ended in Mar. 2026 was ₹62 Mil. Haleos Labs's Revenue for the
three
months ended in Mar. 2026 was ₹751 Mil. Therefore, Haleos Labs's EBITDA margin for the quarter that ended in Mar. 2026 was 8.22%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Haleos Labs EBITDA Margin % Related Terms
Haleos Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Haleos Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:HALEOSLABS vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Haleos Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Haleos Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleos Labs (NSE:HALEOSLABS) has a EBITDA Margin % of 8.22% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haleos Labs and its competitors. This is 31% below median its historical median of 11.94. Over the past decade, Haleos Labs' EBITDA Margin % has ranged from 7.29 to 14.48. According to the industry distribution chart, Haleos Labs ranks #206 out of 935 companies in the Biotechnology industry, placing it in the top 22%.
Is Haleos Labs' EBITDA Margin % too high?
Haleos Labs' current EBITDA Margin % of 8.22% is 31% below median its 10-year median of 11.94. Over the past 10 years, this metric has ranged from a low of 7.29 to a high of 14.48. Based on the distribution chart, Haleos Labs ranks #206 out of 935 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #206 out of 935 companies for EBITDA Margin %. This places Haleos Labs in the top 22% of its industry — outperforming the majority of peers. Historically, Haleos Labs' own EBITDA Margin % has ranged from 7.29 to 14.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haleos Labs and its competitors. Haleos Labs's current EBITDA Margin % is 8.22%, which is 31% below median its own 10-year median of 11.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,123.78, compared to a current price of ₹1,612.30 — trading 43.5% above its estimated fair value. The current EBITDA Margin % is 8.22%, which is 31% below median its 10-year median of 11.94. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current EBITDA Margin % is 8.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,612.30 is trading 43.5% above its estimated GF Value™ of ₹1,123.78.
GuruFocus considers Haleos Labs to be Significantly Overvalued.
Key valuation signals for NSE:HALEOSLABS:
EBITDA Margin %: 8.22% (31% below median its 10-year median of 11.94)
GF Value™: ₹1,123.78 vs. price of ₹1,612.30 (43.5% above fair value)
No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score
Get the complete analysis for NSE:HALEOSLABS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HALEOSLABS has been successfully added to your 
